[Federal Register Volume 64, Number 135 (Thursday, July 15, 1999)]
[Notices]
[Pages 38183-38184]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-18012]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Applications Concerning Dengue Vaccines

AGENCY: U.S. Army Medical Research and Materiel Command, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, and 404.7, announcement is 
made of the availability for licensing of Provisional U.S. Patent 
Applications, Serial Numbers 60/126,311 (filed March 26, 1999) and 
entitled ``Live Attenuated Dengue-3 Vaccine''), 60/126,313 (filed March 
26, 1999 and entitled ``Live Attenuated Multivalent Dengue

[[Page 38184]]

Vaccine''), 60/126,316 (filed March 26, 1999 and entitled ``Adaptation 
of Virus to Vero and Other Vertebrate Cells''), 60/126,317 (filed March 
26, 1999 and entitled ``Dengue-1 Virus Vaccine''), 60/126,318 (filed 
March 26, 1999 and entitled ``Live Attenuated Dengue-4 Vaccine''), and 
60/126,319 (filed March 26, 1999 and entitled ``Live Attenuated Dengue-
2 Vaccine''). These inventions have been assigned to the United States 
Government as represented by the Secretary of the Army.

ADDRESSES: Commanding General, U.S. Army Medical Research and Materiel 
Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort 
Detrick, Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: Mr. Charles Harris, Patent Attorney, 
301-619-2065, or FAX 301-619-5034.

SUPPLEMENTARY INFORMATION: The inventions describe a novel strain of 
dengue virus derived by empirical passage of the virus in primary dog 
kidney cell cultures. Passage of these cells selected for modified 
strains of dengue virus that are attenuated in humans. Human 
inoculation has demonstrated that the strains are safe, cause minimal 
side reactions, but result in infections that stimulate immune 
responses to the virus. It is thought that this immunity will protect 
the recipients from natural infection and diseases caused by the virus 
strains. The invention of Provisional Application SN 60/126,316 relates 
to the description of the use of Vero and other cell lines for the 
production and manufacture of dengue vaccines.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 99-18012 Filed 7-14-99; 8:45 am]
BILLING CODE 3710-08-M